Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL)

the use of dexamethasone, l-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL

Shinichi Kako, Yu Akahoshi, Naonori Harada, Hirofumi Nakano, Kazuaki Kameda, Tomotaka Ugai, Hidenori Wada, Ryoko Yamasaki, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Miki Sato, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun ichi Kimura, Misato Kikuchi, Hideki Nakasone, Rie Yamazaki, Junya Kanda, Junji Nishida & 1 others Yoshinobu Kanda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The effects of intensive regimens and the roles of drugs used might differ between T- and B-lineage acute lymphoblastic leukemia (ALL). We performed a literature search for clinical studies published from January 1998 to March 2013. Studies were eligible for inclusion in the analyses if they included more than 80 patients with adult ALL who were treated with a uniform regimen and compared T- and B-lineage ALL. Studies that included only adolescent or elderly patients were excluded. We identified 11 clinical studies, which included a total of 381 and 1366 patients with T- and B-lineage ALL, respectively, and performed meta-analyses using the selected studies. Nine studies included patients with Philadelphia chromosome-positive (Ph+) ALL. A meta-analysis using the random-effect model demonstrated superior survival in patients with T-lineage ALL compared to those with B-lineage ALL (hazard ratio 1.78, 95 % confidence interval 1.50–2.11), though the inclusion of patients with Ph+ ALL in B-lineage ALL must have influenced this result strongly. We performed meta-regression analyses, adjusted according to whether or not patients with Ph+ ALL were included in each study. Use of dexamethasone (Dex), higher dose of methotrexate (MTX), and higher dose of l-asparaginase (l-asp) were associated with a significant trend toward a better outcome in T-lineage ALL. A meta-regression analysis including Dex and the dose of l-asp or MTX together as covariates showed that these factors were independently significant. In conclusion, the use of Dex and high-dose l-asp or MTX may improve the outcome of T-lineage ALL. This hypothesis should be tested in a prospective study including only patients with Ph-negative ALL.

Original languageEnglish
Pages (from-to)87-92
Number of pages6
JournalAnnals of Hematology
Volume95
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1
Externally publishedYes

Fingerprint

Asparaginase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Dexamethasone
Meta-Analysis
Regression Analysis
Drug Therapy
Philadelphia Chromosome

Keywords

  • Acute lymphoblastic leukemia
  • Dexamethasone
  • l-asparaginase
  • Meta-analysis
  • Methotrexate

ASJC Scopus subject areas

  • Hematology

Cite this

Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL) : the use of dexamethasone, l-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL. / Kako, Shinichi; Akahoshi, Yu; Harada, Naonori; Nakano, Hirofumi; Kameda, Kazuaki; Ugai, Tomotaka; Wada, Hidenori; Yamasaki, Ryoko; Ishihara, Yuko; Kawamura, Koji; Sakamoto, Kana; Sato, Miki; Ashizawa, Masahiro; Terasako-Saito, Kiriko; Kimura, Shun ichi; Kikuchi, Misato; Nakasone, Hideki; Yamazaki, Rie; Kanda, Junya; Nishida, Junji; Kanda, Yoshinobu.

In: Annals of Hematology, Vol. 95, No. 1, 01.01.2016, p. 87-92.

Research output: Contribution to journalArticle

Kako, S, Akahoshi, Y, Harada, N, Nakano, H, Kameda, K, Ugai, T, Wada, H, Yamasaki, R, Ishihara, Y, Kawamura, K, Sakamoto, K, Sato, M, Ashizawa, M, Terasako-Saito, K, Kimura, SI, Kikuchi, M, Nakasone, H, Yamazaki, R, Kanda, J, Nishida, J & Kanda, Y 2016, 'Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, l-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL', Annals of Hematology, vol. 95, no. 1, pp. 87-92. https://doi.org/10.1007/s00277-015-2510-0
Kako, Shinichi ; Akahoshi, Yu ; Harada, Naonori ; Nakano, Hirofumi ; Kameda, Kazuaki ; Ugai, Tomotaka ; Wada, Hidenori ; Yamasaki, Ryoko ; Ishihara, Yuko ; Kawamura, Koji ; Sakamoto, Kana ; Sato, Miki ; Ashizawa, Masahiro ; Terasako-Saito, Kiriko ; Kimura, Shun ichi ; Kikuchi, Misato ; Nakasone, Hideki ; Yamazaki, Rie ; Kanda, Junya ; Nishida, Junji ; Kanda, Yoshinobu. / Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL) : the use of dexamethasone, l-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL. In: Annals of Hematology. 2016 ; Vol. 95, No. 1. pp. 87-92.
@article{bad65744b113416cbacc35553ced1520,
title = "Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, l-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL",
abstract = "The effects of intensive regimens and the roles of drugs used might differ between T- and B-lineage acute lymphoblastic leukemia (ALL). We performed a literature search for clinical studies published from January 1998 to March 2013. Studies were eligible for inclusion in the analyses if they included more than 80 patients with adult ALL who were treated with a uniform regimen and compared T- and B-lineage ALL. Studies that included only adolescent or elderly patients were excluded. We identified 11 clinical studies, which included a total of 381 and 1366 patients with T- and B-lineage ALL, respectively, and performed meta-analyses using the selected studies. Nine studies included patients with Philadelphia chromosome-positive (Ph+) ALL. A meta-analysis using the random-effect model demonstrated superior survival in patients with T-lineage ALL compared to those with B-lineage ALL (hazard ratio 1.78, 95 {\%} confidence interval 1.50–2.11), though the inclusion of patients with Ph+ ALL in B-lineage ALL must have influenced this result strongly. We performed meta-regression analyses, adjusted according to whether or not patients with Ph+ ALL were included in each study. Use of dexamethasone (Dex), higher dose of methotrexate (MTX), and higher dose of l-asparaginase (l-asp) were associated with a significant trend toward a better outcome in T-lineage ALL. A meta-regression analysis including Dex and the dose of l-asp or MTX together as covariates showed that these factors were independently significant. In conclusion, the use of Dex and high-dose l-asp or MTX may improve the outcome of T-lineage ALL. This hypothesis should be tested in a prospective study including only patients with Ph-negative ALL.",
keywords = "Acute lymphoblastic leukemia, Dexamethasone, l-asparaginase, Meta-analysis, Methotrexate",
author = "Shinichi Kako and Yu Akahoshi and Naonori Harada and Hirofumi Nakano and Kazuaki Kameda and Tomotaka Ugai and Hidenori Wada and Ryoko Yamasaki and Yuko Ishihara and Koji Kawamura and Kana Sakamoto and Miki Sato and Masahiro Ashizawa and Kiriko Terasako-Saito and Kimura, {Shun ichi} and Misato Kikuchi and Hideki Nakasone and Rie Yamazaki and Junya Kanda and Junji Nishida and Yoshinobu Kanda",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s00277-015-2510-0",
language = "English",
volume = "95",
pages = "87--92",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL)

T2 - the use of dexamethasone, l-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL

AU - Kako, Shinichi

AU - Akahoshi, Yu

AU - Harada, Naonori

AU - Nakano, Hirofumi

AU - Kameda, Kazuaki

AU - Ugai, Tomotaka

AU - Wada, Hidenori

AU - Yamasaki, Ryoko

AU - Ishihara, Yuko

AU - Kawamura, Koji

AU - Sakamoto, Kana

AU - Sato, Miki

AU - Ashizawa, Masahiro

AU - Terasako-Saito, Kiriko

AU - Kimura, Shun ichi

AU - Kikuchi, Misato

AU - Nakasone, Hideki

AU - Yamazaki, Rie

AU - Kanda, Junya

AU - Nishida, Junji

AU - Kanda, Yoshinobu

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The effects of intensive regimens and the roles of drugs used might differ between T- and B-lineage acute lymphoblastic leukemia (ALL). We performed a literature search for clinical studies published from January 1998 to March 2013. Studies were eligible for inclusion in the analyses if they included more than 80 patients with adult ALL who were treated with a uniform regimen and compared T- and B-lineage ALL. Studies that included only adolescent or elderly patients were excluded. We identified 11 clinical studies, which included a total of 381 and 1366 patients with T- and B-lineage ALL, respectively, and performed meta-analyses using the selected studies. Nine studies included patients with Philadelphia chromosome-positive (Ph+) ALL. A meta-analysis using the random-effect model demonstrated superior survival in patients with T-lineage ALL compared to those with B-lineage ALL (hazard ratio 1.78, 95 % confidence interval 1.50–2.11), though the inclusion of patients with Ph+ ALL in B-lineage ALL must have influenced this result strongly. We performed meta-regression analyses, adjusted according to whether or not patients with Ph+ ALL were included in each study. Use of dexamethasone (Dex), higher dose of methotrexate (MTX), and higher dose of l-asparaginase (l-asp) were associated with a significant trend toward a better outcome in T-lineage ALL. A meta-regression analysis including Dex and the dose of l-asp or MTX together as covariates showed that these factors were independently significant. In conclusion, the use of Dex and high-dose l-asp or MTX may improve the outcome of T-lineage ALL. This hypothesis should be tested in a prospective study including only patients with Ph-negative ALL.

AB - The effects of intensive regimens and the roles of drugs used might differ between T- and B-lineage acute lymphoblastic leukemia (ALL). We performed a literature search for clinical studies published from January 1998 to March 2013. Studies were eligible for inclusion in the analyses if they included more than 80 patients with adult ALL who were treated with a uniform regimen and compared T- and B-lineage ALL. Studies that included only adolescent or elderly patients were excluded. We identified 11 clinical studies, which included a total of 381 and 1366 patients with T- and B-lineage ALL, respectively, and performed meta-analyses using the selected studies. Nine studies included patients with Philadelphia chromosome-positive (Ph+) ALL. A meta-analysis using the random-effect model demonstrated superior survival in patients with T-lineage ALL compared to those with B-lineage ALL (hazard ratio 1.78, 95 % confidence interval 1.50–2.11), though the inclusion of patients with Ph+ ALL in B-lineage ALL must have influenced this result strongly. We performed meta-regression analyses, adjusted according to whether or not patients with Ph+ ALL were included in each study. Use of dexamethasone (Dex), higher dose of methotrexate (MTX), and higher dose of l-asparaginase (l-asp) were associated with a significant trend toward a better outcome in T-lineage ALL. A meta-regression analysis including Dex and the dose of l-asp or MTX together as covariates showed that these factors were independently significant. In conclusion, the use of Dex and high-dose l-asp or MTX may improve the outcome of T-lineage ALL. This hypothesis should be tested in a prospective study including only patients with Ph-negative ALL.

KW - Acute lymphoblastic leukemia

KW - Dexamethasone

KW - l-asparaginase

KW - Meta-analysis

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=84952981153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952981153&partnerID=8YFLogxK

U2 - 10.1007/s00277-015-2510-0

DO - 10.1007/s00277-015-2510-0

M3 - Article

VL - 95

SP - 87

EP - 92

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -